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Abstract
Background: A peripheral blood interferon (IFN) signature (i.e., elevated type I interferon response gene [IRG]
expression) has been described in a subset of patients with rheumatoid arthritis (RA). In the present study, we
systematically assessed the association between this IRG expression and clinical parameters.
Methods: Expression of 19 IRGs was determined in peripheral blood from 182 consecutive patients with RA and
averaged into an IFN score per individual. Correlation and unpaired analyses were performed on the complete
patient group. The analyses were internally validated by using an algorithm to randomize the patient group 1000
times into two equally sized sets, and then analyses were performed on both sets.
Results: Associations were assessed between IFN score and disease duration, 28-joint Disease Activity Score and its
components, the occurrence of erosions and nodules, autoantibody positivity, and immunosuppressive treatment.
This analysis revealed lower IFN scores in patients using hydroxychloroquine, prednisone, and/or sulfasalazine, but it
did not show significant associations between the other parameters and the IFN score. Selecting patients who were
not treated with hydroxychloroquine, prednisone, and/or sulfasalazine (n = 95) did not reveal any significant
associations either.
Conclusions: IRG expression in RA is affected by immunosuppressive treatment with prednisone, hydroxychloroquine,
and/or sulfasalazine, but it is not evidently associated with other clinical parameters. Hence, the IFN signature appears
to describe a subgroup of patients with RA but does not seem to reflect disease activity.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by chronic joint inflammation. It
manifests as a heterogeneous disease that is partly
reflected at the level of gene expression. Genome-wide
gene expression analysis revealed evidence for molecular
differences between patients with RA, in particular in
the type I interferon (IFN) system. Approximately 50%
of patients with RA display a peripheral blood IFN
signature (i.e., relatively high expression of interferon re-
sponse genes [IRGs]) [1].
Type I IFNs were initially known for their antiviral
effects, but increasing insight into their activities re-
vealed their role as pleiotropic cytokines with a critical
role in modulating immune responses, such as cellular
activation, major histocompatibility complex upregula-
tion, induction of apoptosis, and inhibition of angiogen-
esis [2]. It is thought that type I IFNs contribute to
autoimmunity by initiating a break of tolerance (e.g., by
the induction of dendritic cell maturation and inhibition
of regulatory T cells) [3]. The exact role of the IFN sig-
nature in RA is yet unknown, although it was shown to
have potential clinical relevance. That is, (1) the pres-
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for arthritis development in preclinical disease [4], and
(2) the presence of the IFN signature in established RA
was found to be associated with the clinical response to
treatment with rituximab [5] and tocilizumab [6].
Earlier studies have addressed whether the IFN signa-
ture in RA could be associated with clinical parameters,
which inconclusively revealed a potential relationship of
the IFN signature with anticitrullinated protein antibody
(ACPA) titers [7, 8]. However, these study cohorts were
rather small (35 subjects or less) and therefore highly
subject to a lack of power. Hence, the relationships be-
tween the peripheral blood IFN signature and disease-
and inflammation-related clinical parameters have never
been thoroughly assessed. In the present study, we used
a larger cohort of patients with established RA (n = 182)
in combination with a random sampling algorithm to
systematically investigate whether the peripheral blood
IFN signature in RA could be associated with parameters
such as disease activity, laboratory parameters, and the
use of immunosuppressive treatment.
Methods
Patient recruitment and blood collection
Patients with RA (n = 182) were consecutively re-
cruited from the Jan van Breemen Research Institute,
Reade center, Amsterdam, The Netherlands. All pa-
tients were Caucasian and were diagnosed with RA
according to the American College of Rheumatology
1987 criteria [9]. Ninety-five percent of the patients
displayed a 28-joint Disease Activity Score (DAS28)
of ≥3.2 despite earlier treatment with at least two
disease-modifying antirheumatic drugs (DMARDs).
All patients provided written informed consent, and
this study was approved by the medical ethics com-
mittee of Reade. The patients’ characteristics are
shown in Table 1. From all patients, 2.5 ml of blood
was drawn into PAXgene tubes (PreAnalytiX GmbH,
Hombrechtikon, Switzerland) and stored at −20 °C
until further processing.
RNA isolation, complementary DNA synthesis,
and real-time polymerase chain reaction
Total RNA was isolated from the PAXgene tubes ac-
cording to the manufacturer’s instructions. The quantity
and purity of the RNA samples were checked using a
NanoDrop spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). We reverse-transcribed 0.25 μg
of RNA into complementary DNA (cDNA) using a
RevertAid H Minus cDNA Synthesis Kit (Thermo Fisher,
Waltham, MA, USA). A single aliquot of each cDNA
sample was first subjected to 14 cycles of specific target
amplification using a 0.2× mixture of all TaqMan gene
expression assays in combination with the TaqMan Pre-
Amp Master Mix (Applied Biosystems, Foster City, CA,
USA). Following preamplification, the samples were di-
luted 1:5 (vol/vol) in Tris-ethylenediaminetetraacetic
acid buffer, pH 8.0. Multiplex real-time quantitative
polymerase chain reaction was performed using the
96.96 Biomark Dynamic Array systems (Fluidigm Cor-
poration, South San Francisco, CA, USA) at ServiceXS
(Leiden, The Netherlands) according to the manufac-
turer’s instructions. Quantities were calculated relative
to GAPDH using the standard curve method. Expression
levels were log2-transformed.
Calculation of the IFN score and statistical analyses
Nineteen IRGs described to be components of the IFN
signature in RA [1] were measured (see Additional file 1:
Table S1). Log2-transformed expression levels of the
IRGs were highly correlated (r ≥ 0.7 for 90% of the com-
binations, p ≤ 0.002); therefore, an IFN score was
Table 1 Patient characteristics
All patients (n = 182)
Demographic parameters
Age, years, mean (SD) 54.2 (11.8)
Female sex, n (%) 135 (75)
Disease parameters
Disease duration in years, mean (SD) 9.7 (10.3)
DAS28, mean (SD) 5.1 (1.2)
Erosive disease, n (%) 131 (72)
Nodules, n (%)a 43 (24)
Laboratory parameters
ESR, mm/h, mean (SD) 24.5 (18.0)
CRP, mg/L, mean (SD) 17.8 (22.1)
IgM-RF titer, IU/ml, mean (SD)b 124.7 (279)
IgM-RF-positive, n (%)b 95 (59)
ACPA titer, AU/ml, mean (SD)c 1563 (2680)
ACPA-positive, n (%)c 131 (75)
IFN score, mean (SD) 0.26 (1.01)
Medication parameters
MTX use, n (%) 152 (84)
MTX dosage in mg/week, mean (SD) 21.0 (6.3)
Prednisone use, n (%) 52 (29)
Prednisone dosage in mg/day, mean (SD) 7.2 (3.5)
HCQ use, n (%) 35 (19)
SSZ use, n (%) 27 (15)
Abbreviations: ACPA Anticitrullinated protein antibodies, CRP C-reactive protein,
DAS28 28-joint Disease Activity Score, ESR Erythrocyte sedimentation rate, HCQ
Hydroxychloroquine, IFN Interferon IgM-RF Immunoglobulin M rheumatoid fac-
tor, MTX Methotrexate, SSZ Sulfasalazine
aNot available for 6 patients
bNot available for 21 patients
cNot available for 7 patients
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calculated by averaging these values of all genes for each
sample.
Data were analyzed using IBM SPSS Statistics version
22 (IBM, Armonk, NY, USA), R version 3.1.3 [10], and
GraphPad Prism version 5.01 (GraphPad Software, La
Jolla, CA, USA) software. For internal cross-validation, a
1000-times random sampling method was used to
randomize the group of 182 patients into 2 equally sized
sets and to execute Spearman correlation for continuous
variables and Mann-Whitney U analysis for dichotomous
variables on each set [11]. p Values <0.05 were considered
to be significant. Correction for multiple testing was per-
formed using the method of Benjamini and Hochberg.
Results
We studied the association between the peripheral blood
IFN score and the following parameters: disease dur-
ation, DAS28 and its individual components, the occur-
rence of erosions and nodules, autoantibody positivity,
and immunosuppressive treatment. As demonstrated in
Table 2, prednisone use and dose, hydroxychloroquine
(HCQ) use, and sulfasalazine (SSZ) use were the only
variables that showed a significant result, of which only
HCQ use remained significant after correction for mul-
tiple testing. Similar results were obtained in the cross-
validation using the random sampling algorithm, which
revealed significance for HCQ use only: a p value <0.05
Table 2 Analysis of associations between interferon score and clinical parameters after 1000-times random sampling




Significant results (p < 0.05) Median p values
Both sets One set Neither set Set 1 Set 2
Disease parameters
Disease duration 0.061 0.25 0 371 629 0.18 0.20
DAS28 0.18 0.41 0 199 801 0.38 0.32
TJC28 0.10 0.36 0 264 736 0.25 0.25
SJC28 0.61 0.76 1 39 960 0.53 0.59
VAS 0.21 0.44 0 122 878 0.39 0.35
Erosions 0.41 0.60 0 61 939 0.50 0.51
Nodules 0.24 0.46 1 143 856 0.39 0.41
Laboratory parameters
ESR 0.86 0.98 6 18 976 0.60 0.58
ESR dichotomous (>20) 0.71 0.85 0 19 981 0.60 0.58
CRP 0.14 0.39 0 233 767 0.30 0.29
CRP dichotomous (≥10) 0.15 0.38 0 190 810 0.30 0.33
RF titer 0.36 0.60 1 66 933 0.46 0.50
RF positivity 0.96 1.0 3 3 994 0.62 0.61
ACPA titer 0.38 0.59 0 64 936 0.47 0.51
ACPA positivity 0.86 0.98 1 9 990 0.64 0.64
ACPA high positivity (≥3× cutoff) 0.29 0.52 0 79 921 0.44 0.44
RF- and ACPA-positive vs. rest 0.57 0.79 0 34 966 0.59 0.58
RF- and ACPA-negative vs. rest 0.13 0.41 0 219 781 0.27 0.28
Medication parameters
MTX use 2 3 995 0.66 0.65
MTX dosage 0.57 0.79 1 29 970 0.58 0.58
Prednisone use 0.037 0.19 0 526 474 0.14 0.14
Prednisone dosage 0.017 0.14 0 718 282 0.092 0.090
HCQ use 0.001 0.013 521 479 0 0.015 0.015
SSZ use 0.023 0.14 0 584 416 0.11 0.11
PREDN and/or HCQ and/or SSZ use 0.00032 0.0080 612 388 0 0.012 0.010
Abbreviations: BH Benjamini-Hochberg, HCQ Hydroxychloroquine, SSZ Sulfasalazine, PREDN Prednisone, ACPA Anti-citrullinated protein antibodies, CRP C-reactive
protein, DAS28 28-joint Disease Activity Score, DMARD Disease-modifying antirheumatic drug, ESR Erythrocyte sedimentation rate, RF Rheumatoid factor, MTX
Methotrexate, SJC28 Swollen joint count in 28 joints, TJC28 Tender joint count in 28 joints, VAS Visual analogue scale
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was detected in both sets in 521 of the 1000 iterations,
in 1 of the 2 sets for 479 of 1000 iterations, and never in
none of the sets (median p value 0.015). A slight trend
was also observed for prednisone use and dose and SSZ
use (median p values 0.090–0.14, median coefficient for
prednisone dose −0.18), although significance was never
found in both sets for these variables. Each IRG was also
analyzed individually, which revealed similar results
(data not shown).
For prednisone, HCQ, and SSZ treatment, the IFN
score was lower in the treated group than in the un-
treated group. Combining HCQ use, prednisone use,
and SSZ use also revealed a significantly lower IFN score
in patients using HCQ and/or prednisone and/or SSZ
than in patients not treated with any of these agents,
both in the analysis of the complete cohort and in the
cross-validation (p = 0.0080 with Benjamini-Hochberg
correction, median cross-validation p ≤ 0.012) (see
Table 2 and Fig. 1a). Moreover, the suppressive effect ap-
peared larger for patients treated with two or more of
those agents than for patients treated with one agent
(Fig. 1b). No association was found between IFN score
and methotrexate (MTX) treatment or dose. The rela-
tion between IFN score and treatment did not appear to
be confounded by DAS28 or disease duration.
Because the suppression of IFN score in HCQ-, pred-
nisone-, and/or SSZ-treated patients could have a mask-
ing effect on other associations between IFN signature
and clinical parameters, we also performed the analyses
for the selection of patients who were not treated with
prednisone, HCQ, and/or SSZ (n = 95) at the moment of
blood collection. This did not result in any significant
associations between the IFN score and other variables
(uncorrected p value ≥0.099, median p value cross-
validation ≥0.23) (see Additional file 1: Table S2).
Discussion
The present study is the first use of a systematic ap-
proach in a relatively large cohort to study the relation-
ship between the IFN signature in established RA and
clinical parameters. We demonstrated that the IFN sig-
nature was suppressed in patients treated with HCQ,
prednisone, and/or SSZ, but not with MTX. Further-
more, we did not observe any associations between the
IFN signature and the other clinical parameters.
Van der Pouw Kraan et al. showed that a subgroup of
patients with RA displays a common pathogen-response
program, which was characterized by a higher incidence
of the IFN signature as well as higher ACPA titers, sug-
gesting that these parameters might be associated with
one another [7]. However, a causal relationship was not
established, and our data indicate that this is not the
case. The IFN signature was not significantly different
between ACPA-negative and ACPA-positive patients,
nor did it significantly correlate with ACPA titers. Pos-
sibly, the IFN signature and ACPA positivity are inde-
pendently associated with activation of the common
pathogen response program, because they are both im-
plied to be induced via certain pathogens [12, 13].
Our cohort consisted mainly of established patients
with RA with a DAS28 ≥ 3.2 despite treatment with at
least two DMARDs. Although our data do not suggest
any association between IFN score and DAS28 (p > 0.1
in all analyses), we cannot fully exclude the possibility
that significant associations could have been found if the
cohort had included more patients with low disease
Fig. 1 Comparison of interferon (IFN) scores between patients with different disease-modifying antirheumatic drugs and prednisone (PREDN)
treatments. IFN scores were compared between patients who were not treated with PREDN, hydroxychloroquine (HCQ), and sulfasalazine (SSZ)
and patients treated with one or more of those agents. Data from the complete cohort (n = 182) are displayed. a Patients divided into treated or
not with one or more of the three agents. b Patients subdivided into treated with none of the three agents, one of the three agents, or two or
more of the three agents. * p≤ 0.05, *** p≤ 0.001. ns Not significant
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activity. Inclusion of patients with inactive and/or early
disease could provide a more complete view of the IFN
response in different states of the disease.
Remarkably, the IFN scores were decreased in HCQ-,
prednisone-, and/or SSZ-treated patients, even though
the beneficial effects of these treatments were sup-
posedly diminished. Moreover, cotreatment with these
agents appeared to have an additive suppressive effect.
Interference of both prednisone and HCQ with type I
IFN signaling has been described before [14, 15], but the
influence of SSZ remains to be elucidated. It has been
shown that SSZ reduces the levels of RA-related cyto-
kines, such as interleukin-1β and tumor necrosis factor-α
[16], suggesting that SSZ might function through overall
suppression of inflammatory cytokines, including type I
IFNs. Furthermore, it was demonstrated that SSZ is able
to accelerate apoptosis of neutrophils [17], which we have
recently shown to be major inducers of the type I IFN re-
sponse in RA [18]. Consequently, suppression of the type
I IFN response by SSZ might be mediated via an increase
in neutrophil apoptosis.
As previously described, suppression of the IFN score
by certain treatment could affect the applicability of the
IFN signature as a biomarker for therapy response,
particularly to rituximab [5, 19]. That is, the treatment-
related suppression of IFN score might impair the dis-
criminative capacity of the biomarker, which would
consequently lead to more false predictions. Because
multiple studies have demonstrated that the extent of
the IFN signature is highly variable between patients [1,
20, 21], we considered it important to assess the IFN
score as a continuous variable rather than as a dichot-
omous variable. However, inclusion of a healthy control
population would allow us to determine whether pa-
tients with prednisone, SSZ, and/or HCQ treatment
would still display an IFN response above the levels of
healthy control subjects. This could also give more
insight into the applicability of the IFN response as a
biomarker in these patients. Future studies should be
done to elucidate the effect of each individual treatment,
as well as combinatory therapy, on the IFN signature
and the corresponding response prediction. Alterna-
tively, presence of the IFN signature in individuals with
arthralgia was shown to be associated with a higher risk
for developing arthritis [4]. It would be interesting to
study whether early treatment with one of the implied
suppressors of the IFN response could delay or even
prevent disease onset.
Conclusions
Our data indicate that there are no evident associations
between the peripheral blood IFN signature in estab-
lished RA and clinical parameters. This suggests that the
IFN signature is not an indication of disease activity per
se, but its presence could indicate a potential difference
in pathology or immune pathway activation compared
with patients without this signature. Consequently, this
could influence the response to therapy, particularly to
biologics because these are specific modulators of these
immune pathways.
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